Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma
International Journal of Hematology · 2024
DOI: 10.1007/s12185-024-03711-5 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Kenta Hayashino und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama-shi, Okayama, Japan. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, COVID-19, Hepatitis C, Chronic, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Okayama University.
Abstract (Originalsprache)
Although chimeric antigen receptor T-cell (CAR-T) therapies have dramatically improved the outcomes of relapsed/refractory B-cell malignancies, recipients suffer from severe humoral immunodeficiencies. Furthermore, patients with coronavirus disease 2019 (COVID-19) have a poor prognosis, as noted in several case reports of recipients who had COVID-19 before the infusion. We report the case of a 70-year-old woman who developed COVID-19 immediately before CAR-T therapy for high-grade B-cell lymphoma. She received Tixagevimab−Cilgavimab chemotherapy and radiation therapy but never achieved remission. She was transferred to our hospital for CAR-T therapy, but developed COVID-19. Her symptoms were mild and she was treated with long-term molnupiravir. On day 28 post-infection, lymphodepleting chemotherapy was restarted after a negative polymerase chain reaction (PCR) test was confirmed. The patient did not experience recurrence of COVID-19 symptoms or severe cytokine release syndrome. Based on the analysis and comparison of the previous reports with this case, we believe that CAR-T therapy should be postponed until a negative PCR test is confirmed. In addition, Tixagevimab−Cilgavimab and long term direct-acting antiviral agent treatment can be effective prophylaxis for severe COVID-19 and shortening the duration of infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama-shi, Okayama, Japan.
- Department of Hematology and Oncology, Okayama University Hospital, 2-5-1 Shikata, Okayama-shi, Okayama, Japan. pq2k5tsg@okayama-u.ac.jp.
- Division of Blood Transfusion, Okayama University Hospital, 2-5-1 Shikata, Okayama-shi, Okayama, Japan.
- Center for Comprehensive Genomic Medicine, Okayama University Hospital, 2-5-1 Shikata, Okayama-shi, Okayama, Japan.
- Division of Clinical Laboratory, Okayama University Hospital, 2-5-1 Shikata, Okayama-shi, Okayama, Japan.
Förderung
- Okayama University
Zitieren
APA
Hayashino, K., Seike, K., Fujiwara, K., Kondo, K., Matsubara, C., Terao, T., Kitamura, W., Kamoi, C., Fujiwara, H., Asada, N., Nishimori, H., Ennishi, D., Fujii, K., Fujii, N., Matsuoka, K. I., & Maeda, Y. (2024). Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03711-5
Vancouver
Hayashino K, Seike K, Fujiwara K, Kondo K, Matsubara C, Terao T, et al. Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03711-5
BibTeX
@article{Hayashino2024,
author = {Hayashino, Kenta and Seike, Keisuke and Fujiwara, Kanako and Kondo, Kaho and Matsubara, Chisato and Terao, Toshiki and Kitamura, Wataru and Kamoi, Chihiro and Fujiwara, Hideaki and Asada, Noboru and Nishimori, Hisakazu and Ennishi, Daisuke and Fujii, Keiko and Fujii, Nobuharu and Matsuoka, Ken-Ichi and Maeda, Yoshinobu},
title = {Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma},
journal = {International Journal of Hematology},
year = {2024},
doi = {10.1007/s12185-024-03711-5}
}
EUVIMED